Clinical Trial

Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules Compared to the Original Formulation of NPT 2042

Completed Phase 1
View on ClinicalTrials.gov →
Summary
A Single-center, Open-label, Single-dose, Three-period, Fixed Sequence Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-10-29.
Status change: Recruiting → Completed 2026-04-01
Trial Details
NCT Number NCT07222878
Lead Sponsor NeuroPro Therapeutics, Inc.
Conditions Epilepsy, Alzheimer Disease, Epilepsy Intractable
Enrollment 8 participants
Start Date 2025-09-29
Primary Completion 2025-11-04 (estimated)
Study Completion 2025-11-04 (estimated)
Updated on ClinicalTrials.gov 2026-04-03